Finance
Alferon N maker announces private placement of common stock and warrants
Published in Immunotherapy Weekly, September 1st, 2004
Hemispherx Biopharma, Inc., (HEB) has entered into definitive agreements with selected accredited institutional investors, including current shareholders, relating to a private placement of approximately 3.6 million shares of Hemispherx Biopharma's common stock and warrants to purchase up to approximately 1,085,000 additional shares of Hemispherx Biopharma's common stock at $2.08 per unit, for aggregate gross proceeds of approximately $7.5 million.
The 5-year warrants are exercisable at a price of $2.86 per share. Subject to customary closing conditions, the private placement is scheduled to close during the first week of August 2004.
Hemispherx...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Immunotherapy Weekly
Source: Immunotherapy Weekly (2004-09-01)
More Articles from Immunotherapy Weekly
- Allergy
CD28 is required in the effector phase of allergic airway inflammation - Allergy
Sinusitis, rhinosinusitis reclassified by task force as inflammatory diseases - Allergy Medicine
Tolerance in T cells accompanied by effector function in lymphoid organs - Autoimmune Disease
Prostaglandin E2 receptors up-regulated in peritoneal macrophages - Coronavirus
Interferons effective in the treatment of severe acute respiratory syndrome - AIDS/HIV Vaccine
Challenges in the search for HIV vaccine outlined - More from this issue of Immunotherapy Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
